Virus-induced dysfunction of CD4+CD25+ T cells in patients with HTLV-I-associated neuroimmunological disease

Journal of Clinical Investigation

Volumn 115, Issue 5, 2005, Pages 1361-1368

  Yamano, Yoshihisa ^a,b   Takenouchi, Norihiro ^a   Li, Hong Chuan ^c   Tomaru, Utano ^a,d   Yao, Karen ^a   Grant, Christian W ^a   Maric, Dragan A ^a   Jacobson, Steven ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b Kagoshima City Hospital   (Japan)

^c NATIONAL CANCER INSTITUTE   (United States)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD38 ANTIGEN; CD69 ANTIGEN; CELL SURFACE MARKER; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GENE PRODUCT; INTERLEUKIN 2 RECEPTOR ALPHA; PADGEM PROTEIN; TAX PROTEIN; TRANSCRIPTION FACTOR FOXP3;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; HUMAN; HUMAN CELL; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; LYMPHOCYTE SUBPOPULATION; NEUROIMMUNOLOGY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; T LYMPHOCYTE; VIRUS GENE;

EID: 18244370760     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI23913     Document Type: Article

References (57)

1. Osame, M., et al. 1986. HTLV-I associated myelopathy, a new clinical entity [letter]. Lancet. 1:1031-1032.
2. Gessain, A., et al. 1985. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet. 2:407-410.
3. Kaplan, J.E., et al. 1990. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J. Acquir. Immune. Defic. Syndr. 3:1096-1101.
4. Nakagawa, M., et al. 1995. HTLV-I-associated myelopathy: analysis of 213 patients based on clinical features and laboratory findings. J. Neurovirol. 1:50-61.
5. Uchiyama, T. 1997. Human T cell leukemia virus type 1 (HTLV-I) and human diseases. Annu. Rev. Immunol. 15:15-37.
6. Nagai, M., Yamano, Y., Brennan, M.B., Mora, C.A., and Jacobson, S. 2001. Increased HTLV-I proviral load and preferential expansion of HTLV-I Tax-specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP. Ann. Neurol. 50:807-812.
7. Jacobson, S. 2002. Immunopathogenesis of human T cell lymphotropic virus type I-associated neurologic disease. J. Infect. Dis. 186(Suppl. 2):187-192.
8. Osame, M. 2002. Pathological mechanisms of human T-cell lymphotropic virus type I-associated myelopathy (HAM/TSP). J. Neurovirol. 8:359-364.
9. Jacobson, S., Shida, H., McFarlin, D.E., Fauci, A.S., and Koenig, S. 1990. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature. 348:245-248.
10. Yamano, Y., et al. 2002. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood. 99:88-94.
11. Izumo, S., et al. 1989. The neuropathology of HTLV-I associated myelopathy in Japan: report of an autopsy case and review of the literature. In HTLV-I and the nervous system. G.C. Roman, J.C. Vernant, and M. Osame, editors. Alan R. Liss. New York, New York, USA. 261-267.
12. Sakaguchi, S., et al. 2001. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182:18-32.
13. Shevach, E.M. 2002. CD4+ CD25+ suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2:389-400.
14. Baecher-Allan, C., Brown, J.A., Freeman, G.J., and Hafler, D.A. 2001. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol. 167:1245-1253.
15. Takahashi, T., et al. 1998. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10:1969-1980.
16. Thornton, A.M., and Shevach, E.M. 1998. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188:287-296.
17. Shimizu, J., Yamazaki, S., Takahashi, T., Ishida, Y., and Sakaguchi, S. 2002. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat. Immunol. 3:135-142.
18. McHugh, R.S., et al. 2002. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 16:311-323.
19. Read, S., Malmstrom, V., and Powrie, F. 2000. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exp. Med. 192:295-302.
20. Salomon, B., et al. 2000. B7/CD28 costimulatian is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 12:431-440.
21. Takahashi, T., et al. 2000. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192:303-310.
22. Hori, S., Nomura, T., and Sakaguchi, S. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057-1061.
23. Khattri, R., Cox, T., Yasayko, S.A., and Ramsdell, F. 2003. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 4:337-342.
24. Fontenot, J.D., Gavin, M.A., and Rudensky, A.Y. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4:330-336.
25. Lyon, M.F., Peters, J., Glenister, P.H., Ball, S., and Wright, E. 1990. The scurfy mouse mutant has previously unrecognized hematological abnormalities and resembles Wiskott-Aldrich syndrome. Proc. Natl. Acad. Sci. U. S. A. 87:2433-2437.
26. Kanangat, S., et al. 1996. Disease in the scurfy (sf) mouse is associated with overexpression of cytokine genes. Eur. J. Immunol. 26:161-165.
27. Clark, L.B., et al. 1999. Cellular and molecular characterization of the scurfy mouse mutant. J. Immunol. 162:2546-2554.
28. Tivol, E.A., et al. 1995. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 3:541-547.
29. Waterhouse, P., et al. 1995. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 270:985-988.
30. Yamano, Y., et al. 2004. Increased expression of human T lymphocyte virus type I (HTLV-I) Tax11-19 peptide-human histocompatibility leukocyte antigen A*201 complexes on CD4+ CD25+ T cells detected by peptide-specific, major histocompatibility complex-restricted antibodies in patients with HTLV-I-associated neurologic disease. J. Exp. Med. 199:1367-1377.
31. Walker, M.R., et al. 2003. Induction of FoxP3 and acquisition of T regularory activity by stimulated human CD4+CD25- T cells. J. Clin. Invest. 112:1437-1443. doi: 10.1172/JCI200319441.
32. Read, S., et al. 1998. CD38+ CD45RB(low) CD4+ T cells: a population of T cells with immune regulatory activities in vitro. Eur. J. Immunol. 28:3435-3447.
33. Iwashiro, M., et al. 2001. Immunosuppression by CD4+ regulatory T cells induced by chronic retroviral infection. Proc. Natl. Acad. Sci. U. S. A. 98:9226-9230.
34. Richardson, J.H., Edwards, A.J., Cruickshank, J.K., Rudge, P., and Dalgleish, A.G. 1990. In vivo cellular tropism of human T-cell leukemia virus type 1. J. Virol. 64:5682-5687.
35. Okayama, A., et al. 1997. Increased expression of interleukin-2 receptor alpha on peripheral blood mononudear cells in HTLV-I tax/rex mRNA-positive asymptomatic carriers. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 15:70-75.
36. Baecher-Allan, C., Viglietta, V., and Hafler, D.A. 2004. Human CD4+CD25+ regulatory T cells. Semin. Immunol. 16:89-98.
37. Viglietta, V., Baecher-Allan, C., Weiner, H.L., and Hafler, D.A. 2004. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199:971-979.
38. Fujisawa, J., Toita, M., Yoshimura, T., and Yoshida, M. 1991. The indirect association of human T-cell leukemia virus tax protein with DNA results in transcriptional activation. J. Virol. 65:4525-4528.
39. Duyao, M.P., et al. 1992. Transactivation of the c-myc promoter by human T cell leukemia virus type 1 tax is mediated by NF kappa B. J. Biol. Chem. 267:16288-16291.
40. Nicot, C., et al. 2004. HTLV-1-encoded p30II is a post-transcriptional negative regulator of viral replication. Nat. Med. 10:197-201.
41. Weiss, L., et al. 2004. Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood. 104:3249-3256.
42. Baecher-Allan, C., and Hafler, D.A. 2004. Suppressor T cells in human diseases. J. Exp. Med. 200:273-276.
43. Itoyama, Y., et al. 1988. Spontaneous proliferation of peripheral blood lymphocytes increased in patients with HTLV-I-associated myelopathy. Neurology. 38:1302-1307.
44. Sakai, J.A., Nagai, M., Brennan, M.B., Mora, C.A., and Jacobson, S. 2001. In vitro spontaneous lymphoproliferation in patients with human T-cell lymphotropic virus type I-associated neurologic disease: predominant expansion of CD8+ T cells. Blood. 98:1506-1511.
45. Lindley, S., et al. 2005. Defective suppressor function in CD4+CD25+ T-cells from patients with type 1 diabetes. Diabetes. 54:92-99.
46. Baecher-Allan, C., Viglietta, V., and Hafler, D.A. 2002. Inhibition of human CD4(+)CD25(+high) regulatory T cell function. J. Immunol. 169:6210-6217.
47. Belkaid, Y., Piccirillo, C.A., Mendez, S., Shevach, E.M., and Sacks, D.L. 2002. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature. 420:502-507.
48. Aseffa, A., et al. 2002. The early IL-4 response to Leishmania major and the resulting Th2 cell maturation steering progressive disease in BALB/c mice are subject to the control of regulatory CD4+CD25+ T cells. J. Immunol. 169:3232-3241.
49. Hori, S., Carvalho, T.L., and Demengeot, J. 2002. CD25+CD4+ regulatory T cells suppress CD4+ T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice. Eur. J. Immunol. 32:1282-1291.
50. Singh, B., et al. 2001. Control of intestinal inflammation by regulatory T cells. Immunol. Rev. 182:190-200.
51. Sakaguchi, S. 2004. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22:531-562.
52. Salomon, B., and Bluestone, J.A. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19:225-252.
53. Ehrenstein, M.R., et al. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 200:277-285.
54. Viglietta, V., Kent, S.C., Orban, T., and Hafler, D.A. 2002. GAD65-reactive T cells are activated in patients with autoimmune type 1a diabetes. J. Clin. Invest. 109:895-903. doi:10.1172/JCI200214114.
55. Scholz, C., Patton, K.T., Anderson, D.E., Freeman, G.J., and Hafler, D.A. 1998. Expansion of autoreactive T cells in multiple sclerosis is independent of exogenous B7 costimulation. J. Immunol. 160:1532-1538.
56. Hollsberg, P., and Hafler, D.A. 1993. Seminars in medicine of the Beth Israel Hospital, Boston. Pathogenesis of diseases induced by human lymphotropic virus type I infection. N. Engl. J. Med. 328:1173-1182.
57. Osame, M. 1990. Review of WHO Kagoshima meeting and diagnostic guidelines for HAM/TSP. In Human retrovirology HTLV. W. Blattner, editor. Raven Press. New York, New York, USA. 191-197.